Company intelligence / Profile preview

CardioSolv Ablation Technologies

Baltimore, Maryland, USAsbir.gov ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

CardioSolv has developed a patient-specific simulation-based approach to guide catheter ablation in ventricular tachycardia. The technology enables non-invasive prediction of optimal ablation sites prior to procedures, aiming for improved efficacy and reduced complications. The company has completed Phase II SBIR awards and was conducting clinical trials as of late 2019–2025 with the goal of regulatory clearance. No published pivotal trial results yet.

Therapeutic areas: Cardiovascular
Modalities: DeviceSoftware-based simulation tool
Industry: Digital Health Medical Devices

Partnerships

National Institutes of Health/NHLBI via SBIR/STTR grants

Beyond the preview

Go deeper on CardioSolv Ablation Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardioSolv Ablation Technologies.

Explore the full profile